期刊
BRITISH JOURNAL OF CANCER
卷 122, 期 3, 页码 315-328出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41416-019-0615-2
关键词
-
类别
资金
- Spanish Ministry of Economy, Industry and Competitiveness (MEIC) [BFU2016-75008-P]
- Fundacion Vencer El Cancer (VEC)
- European Regional Development Fund (FEDER)
- AGAUR
- FPI fellowship
- Spanish Ministry of Economy, Industry and Competitiveness (MEIC) through the Instituto de Salud Carlos III
- Centro de Excelencia Severo Ochoa
- CERCA Programme/Generalitat de Catalunya
Polycomb repressive complex 2 (PRC2) is a key epigenetic multiprotein complex involved in the regulation of gene expression in metazoans. PRC2 is formed by a tetrameric core that endows the complex with histone methyltransferase activity, allowing it to mono-, di- and tri-methylate histone H3 on lysine 27 (H3K27me1/2/3); H3K27me3 is a hallmark of facultative heterochromatin. The core complex of PRC2 is bound by several associated factors that are responsible for modulating its targeting specificity and enzymatic activity. Depletion and/or mutation of the subunits of this complex can result in severe developmental defects, or even lethality. Furthermore, mutations of these proteins in somatic cells can be drivers of tumorigenesis, by altering the transcriptional regulation of key tumour suppressors or oncogenes. In this review, we present the latest results from structural studies that have characterised PRC2 composition and function. We compare this information with data and literature for both gain-of function and loss-of-function missense mutations in cancers to provide an overview of the impact of these mutations on PRC2 activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据